# Metoprolol vs. Diltiazem in Patients with Angina and Non-Obstructive Coronary Artery Disease with or Without Evidence of Coronary Microvascular Spasm on Acetylcholine Testing

## TL;DR

This study compared metoprolol and diltiazem in patients with angina and non-obstructive coronary artery disease, finding similar outcomes regardless of coronary microvascular spasm status.

## Contribution

The study provides new evidence on the comparable effectiveness of metoprolol and diltiazem in ANOCA patients with or without microvascular spasm.

## Key findings

- No significant differences in SAQ scores between metoprolol and diltiazem in the CMVS group.
- ECG-EST results were comparable with both drugs in both CMVS and NEG groups.
- Short-term symptomatic outcomes were similar regardless of treatment or spasm status.

## Abstract

Background: Pharmacologic therapy guided by invasive coronary function tests (CFTs) may improve symptomatic outcomes in patients with angina and non-obstructive coronary artery disease (ANOCA). In this study, we specifically aimed to investigate whether the induction of coronary microvascular spasm (CMVS) by the acetylcholine (Ach) test predicts a better therapeutic effect of calcium-channel blocker therapy compared to beta-blocker therapy. Methods: We enrolled 31 ANOCA patients, who were divided into two groups according to the result of Ach testing: 16 patients with CMVS (CMVS group) and 15 patients with a negative test (NEG group). Patients with Ach-induced epicardial spasm were excluded. In an open-label crossover trial, patients were randomly assigned to each receive, for a period of 4 weeks, either metoprolol (50 mg twice daily) or diltiazem (120 mg twice daily). At the end of each 4-week period, patients underwent an ECG–exercise stress test (EST) and were invited to fill out the Seattle Angina Questionnaire (SAQ). Results: No significant differences were found between metoprolol and diltiazem in terms of SAQ scores, and ECG-EST results were also largely comparable with the two drug treatments, both in the CMVS group and the NEG group. In particular, the SAQ summary score was 63.1 ± 24 and 66.0 ± 25 (p = 0.59) for metoprolol and diltiazem, respectively, in the CMVS group, and 70.9 ± 17 and 74.3 ± 16 (p = 0.37) with the two drugs, respectively, in the NEG group. Conclusions: Our small open-label study shows that patients with ANOCA with negative Ach test or Ach-induced CMVS show largely comparable short-term symptomatic outcomes and ECG-EST results when treated with either metoprolol or diltiazem.